Receive a copy of our current research models and services product guide.
Revolutionize Drug Discovery with Inotiv’s Comprehensive Neuroscience Program
Target Sufficiency® enables direct, quantitative analysis of drug target systems in cells, biofluids, tissues, and tissue models, including formalin-fixed, paraffin-embedded (FFPE) tissues.
Reduce costs with our complimentary sample for evaluation in your lab.
Search by therapeutic area, research phase, and products and services at inotiv.com.
Inotiv delivers a broad array of nonclinical and analytical services from discovery through clinical development.
Inotiv provides the broadest range of research models and related services to pharmaceutical and biotech companies, government, academia, and other life science organizations.
November 21, 2024 Acquiring and Developing Services and Resources to Build a Full Service, Customer-Focused CRO has Fueled 847% Revenue Growth ...
November 20, 2024 WEST LAFAYETTE, Ind., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company” or “Inotiv”),&...
November 14, 2024 Inotiv is incredibly pleased to announce that we’ve received a $1.8 million dollar grant to develop a novel chronic kidney disease (CKD) in vivo model that can bridge the...
How Differences Between Experimental IBD Models Can Impact Your Drug Development Program
Due to the current FDA concern and guidance on reducing the risk of Nitrosamine impurities in human drugs, there has been an increased industry need for testing of these impurities using the Bacterial Reverse Mutation (Ames) test. As Nitrosamines are not readily detectable by standard Ames methodologies, specifically cited in the Ames testing guideline (OECD 471), the need for a robust protocol better suited for this class of compounds is warranted.
Copyright © 2024 Inotiv. All Rights Reserved.